About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

Merck Recalls Cholesterol Drug Liptruzet

Company issues recall due to defects in product packaging
TUESDAY, Jan. 14, 2014 (HealthDay News) -- Packaging defects have prompted a recall of the combination cholesterol drug Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.
Merck said the foil pouches holding Liptruzet pills could allow air and moisture inside, potentially decreasing the drug's effectiveness. The recall covers all four dose strengths and every batch that's gone out since Liptruzet hit the market in May.
Liptruzet combines atorvastatin and Zetia (ezetimibe). Cardiologists expect no health problems to result from the recall, in part because both atorvastatin and Zetia will remain available separately.
"Patients are not going to be in any harm's way just going on atorvastatin until this packaging issue gets corrected," Kevin Marzo, M.D., chief of cardiology at Winthrop-University Hospital in Mineola, N.Y., told HealthDay.
Full Article (http://consumer.healthday.com/cardiovascular-health-information-20/dietary-choloesterol-news-130/merck-recall-cholesterold-drug-liptruzet-683861.html )
Health Headlines
New Treatment Approved for Rare Form of HemophiliaView in a lightbox
Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid DelayedView in a lightbox
Few U.S. Hospitals Ready to Handle Ebola, Survey FindsView in a lightbox
New York City Ebola Patient in Stable ConditionView in a lightbox
Nurse Nina Pham Heading Home After Beating EbolaView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices | Talks Your Health